Exact Mass: 607.1963808
Exact Mass Matches: 607.1963808
Found 74 metabolites which its exact mass value is equals to given mass value 607.1963808
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
4-O-Phosphohygromycin B
Cys His Trp Tyr
Cys His Tyr Trp
Cys Asn Trp Trp
Cys Trp His Tyr
Cys Trp Asn Trp
Cys Trp Trp Asn
Cys Trp Tyr His
Cys Tyr His Trp
Cys Tyr Trp His
His Cys Trp Tyr
His Cys Tyr Trp
His Trp Cys Tyr
His Trp Tyr Cys
His Tyr Cys Trp
His Tyr Trp Cys
Asn Cys Trp Trp
Asn Trp Cys Trp
Asn Trp Trp Cys
Trp Cys His Tyr
Trp Cys Asn Trp
Trp Cys Trp Asn
Trp Cys Tyr His
Trp His Cys Tyr
Trp His Tyr Cys
Trp Asn Cys Trp
Trp Asn Trp Cys
Trp Trp Cys Asn
Trp Trp Asn Cys
Trp Tyr Cys His
Trp Tyr His Cys
Tyr Cys His Trp
Tyr Cys Trp His
Tyr His Cys Trp
Tyr His Trp Cys
Tyr Trp Cys His
Tyr Trp His Cys
Torin 1
Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy. Torin 1 is a potent inhibitor of mTOR with an IC50 of 3 nM. Torin 1 inhibits both mTORC1/2 complexes with IC50 values between 2 and 10 nM. Torin 1 is an effective inducer of autophagy.
Atopaxar hydrobromide
C29H39BrFN3O5 (607.2056955999999)
C78275 - Agent Affecting Blood or Body Fluid > C1327 - Antiplatelet Agent
N-[(2R,4aS,12aR)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-Acetyl-N-[1-(1,1-biphenyl-4-ylmethyl)-2-oxoazepan-3-YL]-3-formyl-O-phosphonotyrosinamide
Montelukast sodium
C35H35ClNNaO3S (607.1923750000001)
D019141 - Respiratory System Agents > D018927 - Anti-Asthmatic Agents > D020024 - Leukotriene Antagonists D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006727 - Hormone Antagonists D065693 - Cytochrome P-450 Enzyme Inducers > D065694 - Cytochrome P-450 CYP1A2 Inducers COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials C78273 - Agent Affecting Respiratory System > C29712 - Anti-asthmatic Agent Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
N-coumaroyl tyramine-4,4-O-beta-D-diglucoside
C29H37NO13 (607.2264792000001)
[(1S,2S,3R,4S,6R)-2-[(3aS,4S,4R,5S,6R,7S,7aS)-6-[(1R)-1-amino-2-hydroxyethyl]-3,4,5,7-tetrahydroxy-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,2-oxane]-4-yl]oxy-6-amino-3-hydroxy-4-(methylamino)cyclohexyl] dihydrogen phosphate
[(2R)-2-[(3S,3aS,4S,4R,6R,7S,7aS)-4-[(1R,2S,3R,5S,6R)-3-amino-2,6-dihydroxy-5-(methylamino)cyclohexyl]oxy-3,4,5,7-tetrahydroxy-6-(hydroxymethyl)spiro[4,6,7,7a-tetrahydro-3aH-[1,3]dioxolo[4,5-c]pyran-2,6-oxane]-2-yl]-2-aminoethyl] dihydrogen phosphate
6-[2-(Oxylatosulfonyl)-4-(hydroxysulfonyl)phenyl]-3,4,8,9-tetrahydro-1,14:11,12-dipropano-2H,10H-1-azonia-11-aza-13-oxapentacene
C31H31N2O7S2+ (607.1572596000001)
N-[(2S,4aR,12aR)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-[(2R,4aR,12aS)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-[(2S,4aS,12aS)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-[(2R,4aR,12aR)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-[(2S,4aR,12aS)-2-[2-(2,3-dihydro-1H-inden-2-ylamino)-2-oxoethyl]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-8-yl]-4-(trifluoromethyl)benzamide
C33H32F3N3O5 (607.2293937999999)
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-[3-(trifluoromethyl)phenyl]-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-3-methoxy-N-methylbenzenesulfonamide
2-[(2R,4aS,12aS)-8-[(3-methoxyphenyl)sulfonylamino]-5-methyl-6-oxo-2,3,4,4a,12,12a-hexahydropyrano[2,3-c][1,5]benzoxazocin-2-yl]-N-(4-propan-2-ylphenyl)acetamide
C32H37N3O7S (607.2352092000001)
N-[(4R,7R,8S)-5-(4-chlorophenyl)sulfonyl-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-oxanecarboxamide
(1s,2s,3s,4s,5r,6r,7s,9r,12r)-4,5,12-tris(acetyloxy)-6-[(acetyloxy)methyl]-2,3-dihydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl pyridine-3-carboxylate
C29H37NO13 (607.2264792000001)
(3s,6r,9s,12s,16r,18s)-6-[(3-bromo-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3,7,9,12,16,18-hexamethyl-14-methylidene-1-oxa-4,7,10-triazacyclooctadeca-4,10-diene-2,8,15-trione
C28H38BrN3O7 (607.1892978000001)
(3s,6s,9r,12s,16s,18r)-6-[(3-bromo-4-hydroxyphenyl)methyl]-5,11-dihydroxy-3,7,9,12,16,18-hexamethyl-14-methylidene-1-oxa-4,7,10-triazacyclooctadeca-4,10-diene-2,8,15-trione
C28H38BrN3O7 (607.1892978000001)
(2s,9s,9as)-9-hydroxy-9-{[(1r,4s)-3-hydroxy-1-methyl-6-oxo-1h,4h-pyrazino[2,1-b]quinazolin-4-yl]methyl}-2-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2h,9ah-imidazo[1,2-a]indol-3-one
9-hydroxy-9-({3-hydroxy-1-methyl-6-oxo-1h,4h-pyrazino[2,1-b]quinazolin-4-yl}methyl)-2-methyl-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2h,9ah-imidazo[1,2-a]indol-3-one
(2s,9s,9as)-9-hydroxy-9-{[(1s,4s)-3-hydroxy-1-methyl-6-oxo-1h,4h-pyrazino[2,1-b]quinazolin-4-yl]methyl}-2-methyl-1-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2h,9ah-imidazo[1,2-a]indol-3-one
(1r,2r,3s,4s,5s,6s,7s,9s,12r)-4,5,12-tris(acetyloxy)-6-[(acetyloxy)methyl]-2,3-dihydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl pyridine-3-carboxylate
C29H37NO13 (607.2264792000001)
4,5,12-tris(acetyloxy)-6-[(acetyloxy)methyl]-2,3-dihydroxy-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl pyridine-3-carboxylate
C29H37NO13 (607.2264792000001)